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A B S T R A C T
Lung transplantation (LTx) is the last treatment for patients suﬀering from end-stage lung diseases. Survival post-
LTx is hampered by the development of the bronchiolitis obliterans syndrome (BOS) and diagnosis is often late.
Given the urgent clinical need to recognize BOS patients at an early stage, we analyzed circulating miRNAs to
identify possible stratiﬁcation markers for BOS development post-transplantation. Therefore, pro-ﬁbrotic (miR-
21, miR-155), anti-ﬁbrotic (miR-29a) and ﬁbrosis-unrelated (miR-103, miR-191) miRNAs were analyzed in
serum of end-stage lung disease patients and during LTx follow-up.
Signiﬁcant elevated levels of serum miRNAs were observed for all investigated miRNAs in both chronic
obstructive pulmonary disease and interstitial lung disease patients compared to healthy controls. The same
miRNAs were also signiﬁcantly increased in the serum of BOS+ vs. BOS− patients. Most importantly, miR-21,
miR-29a, miR-103, and miR-191 levels were signiﬁcantly higher in BOS+ patients prior to clinical BOS
diagnosis.
We demonstrated that a selected group of miRNAs investigated is elevated in end-stage lung disease and BOS
+ patients, prior to clinical BOS diagnosis. Even if further research is expedient on the prognostic value of
circulating miRNAs in BOS and lung conditions in general, these results strongly suggest that circulating miRNAs
could be used as potential biomarkers for BOS development.
1. Introduction
Lung transplantation (LTx) is the last treatment option for patients
suﬀering from end-stage lung diseases. Survival after LTx is severely
hampered by the development of chronic lung allograft dysfunction,
which can manifest in a restrictive form, restrictive allograft syndrome
(RAS), or an obstructive form. The latter is deﬁned as bronchiolitis
obliterans (BO), and occurs in approximately 50% of LTx patients
within 5 years after the transplantation [1]. BO is diagnosed via a
surrogate marker, i.e. decline of the FEV1 of 80% compared to baseline
levels and is referred to as bronchiolitis obliterans syndrome (BOS).
This diagnosis is often late and therefore there is urgent clinical need
for novel biomarkers to identify patients at risk for BOS development at
an earlier stage [2].
Micro-RNAs (miRNAs) are short non-coding RNAs, that inhibit gene
expression at the post-transcriptional level by binding to the 3’UTR of
target messenger-RNAs, thereby promoting their degradation or inhi-
biting translation [3]. Besides representing crucial endogenous regula-
tors of gene expression within the cell, miRNAs can be found in
biological ﬂuids, including plasma, serum, breast milk etc., although
their role in circulation is still largely unknown. The levels of circulat-
ing miRNAs were found to be either elevated or decreased in various
transplantation settings, including kidney, heart, liver, and small
intestine transplantation [4]. Interestingly, it is still unknown whether
clinical parameters in LTx are also associated with levels of circulating
miRNAs.
In this study we hypothesized that selected miRNAs could serve as
stratiﬁcation markers for patients who do or do not develop BOS after
LTx and thereby function as novel diagnostic biomarker to identify
patients at risk for BOS development. For this end, we analyzed the
levels of diﬀerent miRNAs in a cohort of LTx patients that did or did not
develop BOS post-LTx. Furthermore, we investigated the levels of these
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selected miRNAs in patients suﬀering from end-stage lung diseases. Our
results show that a panel of selected miRNAs might prove to be
beneﬁcial to early identify patients who develop BOS post-LTx.
2. Patients and methods
2.1. Patients and sampling
All selected patients included in this study were transplanted at the
Heart and Lung Center of the University Medical Center Utrecht in The
Netherlands between May 2003 and September 2010. All patients gave
informed consent and the study was approved by the medical ethical
committee. Furthermore, all methods were carried out in accordance
with the approved guidelines within our center.
Patient blood was drawn in serum tubes and centrifuged for 10 min
at 2000 ×g. Serum was isolated and stored at −80 °C until further
usage. For our analyses, we selected pre-LTx serum samples, drawn
shortly prior to transplantation. For our follow-up experiments we used
a quartile-based selection method [5]. We selected serum samples
collected at 4 time points (quartiles) equally-distributed from the time
of transplant until BOS diagnosis (quadrant-based selection). For
clariﬁcation, the time between the transplantation date and the clinical
diagnosis of BOS was divided by 4 to generate quartiles for each
patient. Subsequently, serum obtained at each quartile was selected for
further analysis. For each BOS+ patient, a matched BOS− patient with
similar follow-up length was selected in parallel. Therefore there is no
diﬀerence in follow-up time between BOS+ and BOS− patients, this is
illustrated further in Table 1.
2.2. miRNA isolation and quantiﬁcation
Serum RNA, including miRNAs, was extracted from 200 μl of serum
isolated from patients and previously stored at −80 °C, by using the
miRCURY™ RNA Isolation Kit for Bioﬂuids (Exiqon, Denmark) accord-
ing to the manufacturer's instructions. cDNA was synthesized from
2,5 μl of serum-RNA by using individual miRNA-speciﬁc RT primers
contained in the TaqMan Human miRNA assay in the presence of 3.3 U/
μl MultiScribe RT enzyme (Lifetechnologies, USA), by using the
following thermal cycler conditions: 10 min, 4 °C; 30 min, 16 °C;
20 min, 42 °C; 5 min, 85 °C. Circulating miRNA levels were quantiﬁed
in duplicate from 3 μl cDNA, with TaqMan Fast Advance Master Mix
and speciﬁc primers of the TaqMan Human miRNA assay, using the
following ampliﬁcation condition on the Quantstudio 12k ﬂex Real-
Time PCR system (Lifetechnologies, USA): 2 min, 50 °C; 20 s, 95 °C;
40 cycles of 1 s, 95 °C; 20 s, 60 °C. RTqPCR data were analyzed via the
comparative threshold cycle method [6]. The abundance of each
circulating miRNA was expressed as relative fold change (FC) as
compared to the median level detected among all patients set as 1.
2.3. Statistics
Statistical analysis was performed using GraphPad Prism software
version 6.02 (GraphPad Software, USA) and SPSS version 20 (IBM
Corp., Armonk, NY). The normally distributed log2-transformed FC
results were analyzed via usage of the Kruskal-Wallis test and two-way
ANOVA and the Dunn's multiple comparisons test for multiple testing
comparison with power of test set at α= 0.05. Values for end-stage
lung disease patients and healthy controls (HC) were tested for
Gaussian distribution via the D'Agostino-Pearson omnibus normality
test and subsequently analyzed via the Mann-Whitney test. A p < 0.05
was considered to be statistically signiﬁcant.
3. Results
3.1. Patients and miRNA selection
The cohort of end-stage lung disease patients consisted of patients
suﬀering from chronic obstructive pulmonary disease (COPD, n= 5),
cystic ﬁbrosis (CF, n= 5), and interstitial lung disease (ILD, n= 5). All
patients were treated with standardized immunosuppressive therapy
consisting of tacrolimus, basiliximab, prednisone, and mycophenolate
mofetil. Incidentally, patients that were deﬁned as being at high risk for
either CMV or EBV reactivation (CMV−/EBV− patient and CMV+/
EBV+ donor) were treated with valganciclovir up until 6 months after
transplantation. For follow-up analyses we included 10 BOS+ and 10
BOS− patients matched for underlying disease prior to transplantation,
age, and gender (Table 1), resulting in a total of 80 serum miRNA level
determinations. None of the patients analyzed presented with episodes
of acute rejection or infections. Also, no RAS was observed, as
determined by international guidelines [1].
We hypothesized that ILD patients (diagnosis for lung allocation
score: other pulmonary ﬁbrosis) might present higher pro-ﬁbrotic
miRNA levels, because prolonged ILD is often associated with pulmon-
ary ﬁbrosis. Additionally, BOS is associated with extensive pulmonary
ﬁbrosis [2]. Therefore, we selected two pro-ﬁbrotic miRNAs, miR-21
(5p, TaqManID: 000397) and miR-155 (5p, TaqManID: 002623), given
their association with multiple ﬁbrotic conditions, including diﬀerent
transplantation settings, in literature [7–9]. Based on previous knowl-
edge on these conditions, we also selected an anti-ﬁbrotic miRNA, miR-
29a (3p, TaqManID: 002112), and control miRNAs unrelated to ﬁbrosis,
i.e. miR-103 (5p, TaqManID: 121218) and miR-191 (5p, TaqManID:
002299) [10]. All selected miRNAs are identiﬁed as potential biomar-
kers for various diseases, conﬁrming there relative abundancy in serum
[9,11–14].
3.2. Levels of selected serum miRNAs are elevated in end-stage lung disease
patients compared to healthy controls
The qPCR analysis revealed that all the selected miRNAs were
signiﬁcantly increased in the pre-transplant serum of patients suﬀering
from end-stage lung diseases as compared to healthy controls (HC,
Fig. 1A–E). Moreover, when stratiﬁed per type of lung disease, all the
serum miRNAs investigated were signiﬁcant elevated in both COPD and
Table 1
Clinical and demographic proﬁle of lung transplantation patients
Overview of selected BOS+ and BOS− patients. No diﬀerences were observed
between the matched BOS+ and BOS- patients as indicated by the respective p-values.
BOS: bronchiolitis obliterans syndrome, COPD: chronic obstructive pulmonary disease,
CF: cystic ﬁbrosis.
BOS Non BOS p-Value
Total number 10 10
BOS grade
I 6 N.A.
II 3 N.A.
III 1 N.A.
Onset of BOS 35 (23–59) N.A.
(month)
Mean follow up (months) 43 (24–104) 60 (26–103) 0.105
Quartiles (months)
I 9 (6–17) 9 (5–15) 0.861
II 18 (12−30) 18 (11–29) 0.986
III 27 (18–45) 28 (16–48) 0.832
IV 38 (24–61) 38 (24–63) 0.905
Type of transplantation
Single 4 2 0.329
Bilateral 6 8
Mean age (years) 43 (16–61) 43 (21–61) 0.957
Gender
Male 2 2 1.000
Female 8 8
Primary disease
COPD 6 6 1.000
CF 4 4
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ILD patients compared to HC. No diﬀerences between the diagnostic
clusters CF, COPD, and ILD were observed (Fig. 2F–J).
3.3. Selected serum miRNAs are elevated in BOS+ patients compared to
matched BOS− patients
We next investigated whether BOS patients had consistently high
serum levels of miRNAs post-transplant or whether these levels
increased further at the time of BOS development. To this end, serially
obtained post-transplant sera were analyzed for miRNA levels. The time
from lung transplant until the onset of BOS of each patient was divided
into four equal quadrants and one sample taken in the middle of each
quadrant was analyzed. Analysis of these serum samples demonstrated
that the levels of all analyzed miRNAs, except for mir-191, showed a
similar pattern, and were overall signiﬁcantly increased in the serum of
BOS+ vs. BOS− patients. In addition, this elevation was already
present in mir-21, mir-29a, mir103, and mir-155 prior to the clinical
diagnosis of BOS (see Fig. 2).
4. Discussion
In this study, we investigated the presence of selected miRNAs in
serum of both end-stage lung disease patients prior to LTx as well as in
serum of a follow-up cohort post-LTx consisting of both BOS+ and
BOS− patients. Our results show that all selected pro-ﬁbrotic, miR-21
and miR-155, anti-ﬁbrotic, miR-29a, and ﬁbrosis-unrelated, miR-103
and miR-191, miRNAs were elevated in end-stage lung disease patients.
Given that the levels of circulating miRNAs are consistently higher in
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Fig. 1. Levels of serum miRNAs are elevated in end-stage lung diseases compared to healthy controls. The levels of serum miRNAs were analyzed by RTqPCR as described in the text in the
serum of patients after lung transplant and represented as log2FC. Micro-RNAs were quantiﬁed in the serum of patients with end-stage lung diseases and are depicted as box and whisker
plots, where boxes are indicating the median and the 25th to 75th percentiles and the whisker the min and max values within each diagnostic group. CF: cystic ﬁbrosis, ILD: interstitial
lung disease, COPD: chronic obstructive pulmonary disease, HC: healthy controls, FC: fold change, *p < 0.05, **p < 0.01.
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Fig. 2. BOS+ patients present higher levels of selected serum miRNAs compared to matched BOS− patients. The impact of time and BOS development on the level of circulating miRNAs
was analyzed by using the two-way ANOVA, setting time and disease as variables. Relative miRNA levels are depicted as log2FC (Mean + SEM). Taken together, all diﬀerent miRNAs,
except miR-191, were signiﬁcant elevated in BOS+ compared to BOS− groups (p < 0.04, individual p values depicted per graph). BOS+, n= 10, BOS−, n= 10 (A–E).
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patients with end-stage lung diseases, we investigated whether this was
maintained after transplantation and/or exacerbated in case of BOS
development. We show that selected miRNAs, including mir-21, mir-
29a, mir-103, and mir-155, are elevated in patients who develop BOS
and that these elevated levels are measurable prior to any clinical
manifestations.
Despite the relatively small cohort sizes, we showed that the
presence of an inﬂammatory lung disease is associated with increased
levels of circulating miRNAs. Interestingly, the ILD patients investi-
gated did not exhibit elevated levels of pro-ﬁbrotic or diminished levels
of anti-ﬁbrotic miRNAs compared to other end-stage lung diseases,
despite the pulmonary ﬁbrosis which is often observed in these patients.
Intriguingly, both pro- and anti-ﬁbrotic miRNAs, as well as ﬁbrosis-
unrelated miRNAs, were found increased in the circulation of BOS+
patients and in patients suﬀering from other forms of inﬂammatory
lung diseases not related to transplant complications. Micro-RNAs are
actively secreted from cells via exosomes. Also, it is proposed that
miRNAs can be released in the extracellular compartments upon cell
injury and cell death, e.g., due to the prolonged exposure to an
immune-activated environment [4], often present in the pathogenesis
of BOS and end-stage lung diseases [1]. These inﬂammatory processes
diminish upon transplantation [2], and this might be reﬂected by lower
levels of serum miRNAs, as observed in BOS− patients. On the
contrary, patients that cannot counteract the chronic inﬂammation
even after LTx and are thereby characterized by an increased abun-
dance of circulating miRNAs, might be the ones developing BOS. Even if
the discriminative value of either pro- or anti-ﬁbrotic miRNAs is
limited, the combination of selected miRNAs could perhaps improve
this distinction. However, a full miRNA proﬁling, including lung-
enriched and inﬂammatory candidates, and deeper investigations are
desirable to further establish these observations and to prove these
hypotheses.
The overall increase of serum miRNAs in BOS+ patients could be
detected before the actual diagnosis of BOS, suggesting that the
detection of elevated circulating miRNAs might serve as early biomar-
kers for BOS development. Further supporting this concept, serum
miRNAs have been proposed as potential prognostic biomarkers in
diﬀerent transplantation settings [4,15,16]. Due to cohort constrains
we were not able to assess potential correlations between the miRNAs
investigated in this study and other biomarkers, including inﬂamma-
tory cytokines. Previously, our group identiﬁed sCD59 as a biomarker
for BOS development [17]. However, for these patients the miRNA
analysis did not improve the distinction between being at risk for BOS
development, which could be attributed to small patient numbers.
Therefore, the additive value of miRNAs in the clinical diagnosis of BOS
remains unclear.
Dysregulated expression of other miRNAs was observed in periph-
eral mononuclear cells of BOS patients with donor speciﬁc-HLA
antibodies, further stressing the importance of miRNA regulation in
this transplant complication [18] and their potential value as biomar-
kers for this condition validated. LTx patients identiﬁed as being at risk
for BOS development by using such miRNA-biomarkers could therefore
undergo alternative treatment regimens, which could potentially
restrain disease progression and delay clinical manifestations. Overall
miRNA abundancy in serum was comparable to miRNA levels obtained
from bronchoalveolar lavage ﬂuid samples and acquired Ct values were
all within measurable range (data not show). As circulatory miRNAs are
easily accessible and highly stable in human blood, they would
represent profoundly good biomarkers for routine diagnostic follow-
up after transplantation procedure [10].
In summary, we demonstrated that a selected group of miRNAs is
elevated in BOS+ patients compared to BOS- patients and this
diﬀerence is present prior to the clinical diagnosis of BOS. This work
opens new perspectives for future research aimed to further elucidate
the prognostic value of circulating miRNAs in BOS and lung conditions
in general.
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